articleThe LancetJun 16, 2023GREEN OA

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

ADArvind DasariSLSara LonardiRGRocio García‐CarboneroÉEÉlena ElezTYTakayuki Yoshino

The University of Texas MD Anderson Cancer Center · Istituto Oncologico Veneto · +37 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

312
total citations
FWCI
72.17
Percentile
100%
References
17
Citations per year

Authors

37

Topics & keywords

Topics
Keywords
  • Medicine
  • Regorafenib
  • Internal medicine
  • Clinical endpoint
  • Colorectal cancer
  • Placebo
  • Phases of clinical research
  • Oncology
No related works found for this paper.